Crestor and Trazodone Interaction: What Clinicians and Patients Should Know

The direct answer

Rosuvastatin and trazodone can generally be taken together. Rosuvastatin is cleared mainly by the kidneys and hepatic transporters rather than by CYP3A4, the enzyme trazodone requires to form its active metabolite, so neither drug is expected to meaningfully raise the other's blood level under current FDA labeling for each drug [3][7]. The clinically relevant overlap is pharmacodynamic rather than pharmacokinetic: trazodone causes dose-dependent dizziness and orthostatic hypotension through alpha-1 receptor blockade, and rosuvastatin causes dizziness less often but not never, so the two effects can add up in a given patient, especially an older adult or someone starting or increasing trazodone [4][7][3]. No published interaction trial has tested this specific pairing directly; the assessment above is built from each drug's independent pharmacology and labeling, not from a combined-arm study.

The useful clinical question here is not whether Crestor and trazodone share a metabolic pathway. They largely do not. The useful question is whether their separate effects on blood pressure and alertness are large enough, in a given patient, to justify a short structured monitoring window rather than assuming the "minor" database rating settles the matter.

Why this pairing raises the question at all

Patients on a statin for cardiovascular risk reduction who are also prescribed trazodone for insomnia or depression reasonably ask whether the combination is safe. Statins as a drug class carry well-documented interaction risks, and trazodone has its own interaction profile tied to CYP3A4 metabolism, so the concern is not misplaced even though the answer for this particular statin is reassuring [1].

Unlike simvastatin and atorvastatin, rosuvastatin undergoes minimal cytochrome P450-mediated metabolism. According to its FDA label, approximately 90 percent of a rosuvastatin dose is excreted unchanged, with the small remaining fraction metabolized mainly through CYP2C9 [3][2]. Rosuvastatin is not a CYP3A4 substrate, inhibitor, or inducer per its label [3]. Trazodone, in contrast, depends on CYP3A4 for its main metabolic pathway to mCPP [4]. Drugs that strongly inhibit or induce CYP3A4 can meaningfully change trazodone exposure; rosuvastatin is not one of them.

Do rosuvastatin and trazodone share a metabolic pathway?

They largely travel through separate routes, which is the main reason the pharmacokinetic interaction risk stays low.

Rosuvastatin's clearance depends on hepatic uptake transporters OATP1B1 and OATP1B3 plus the efflux transporter BCRP [5]. Drugs that inhibit these transporters, such as cyclosporine, certain protease inhibitors, and gemfibrozil, are the ones known to raise rosuvastatin exposure meaningfully. Trazodone has not been shown to inhibit OATP1B1, OATP1B3, or BCRP in available data, so it is not expected to raise rosuvastatin levels through transporter inhibition [4].

Going the other direction, rosuvastatin's lack of CYP3A4 activity means it is not expected to alter trazodone metabolism. The trazodone label specifically warns about co-administration with strong CYP3A4 inhibitors such as ketoconazole and ritonavir and recommends dose reduction in that setting; no comparable warning applies to statins that bypass CYP3A4 [7].

Rosuvastatin also undergoes a minor CYP2C9-mediated step producing the weakly active metabolite N-desmethyl rosuvastatin [2]. Trazodone is not a known CYP2C9 inhibitor, so this minor pathway is not expected to be affected either.

For context, the JUPITER trial (N=17,802) found rosuvastatin 20 mg daily reduced the primary composite cardiovascular endpoint by roughly 44 percent compared with placebo in adults with elevated C-reactive protein and normal LDL-C [6]. That trial establishes rosuvastatin's cardiovascular benefit at a population level; it was not designed to evaluate concomitant trazodone use, and no subgroup data on that combination is available from it.

The real consideration: additive dizziness and orthostatic hypotension

This is where the interaction question shifts from pharmacokinetics to pharmacodynamics, and where clinical attention is better spent.

Trazodone causes orthostatic hypotension through alpha-1 adrenergic receptor blockade. The effect is dose-dependent and most pronounced during initiation and dose increases [4]. The trazodone label's adverse reaction data describe dizziness occurring in a substantial minority of patients at therapeutic antidepressant doses of 150 to 400 mg daily; the exact percentage should be checked against the current label text before being quoted to a patient, since labeling can be revised [7].

Rosuvastatin causes dizziness less often. Labeling adverse-reaction data describe dizziness at a low single-digit rate that is only modestly above placebo [3]. The mechanism is not fully established but is presumed related to mild blood-pressure effects seen with statin therapy generally rather than a distinct pharmacologic action.

The additive risk is modest on average but matters more for specific patients: older adults, patients on antihypertensives, and patients with autonomic dysfunction. The American Geriatrics Society's Beers Criteria identifies trazodone as a medication associated with orthostatic hypotension and falls in adults 65 and older, independent of any statin co-therapy [8].

How drug interaction databases rate this pair, and how much weight that should carry

Commercial drug interaction databases classify the rosuvastatin-trazodone pairing as low risk. Lexicomp lists it in a "monitor" category, the tier used for combinations where awareness is warranted but no routine dose change or avoidance is recommended. Clinical Pharmacology (Elsevier) rates it "minor." These platforms are proprietary editorial tools that synthesize pharmacology and case reports; they are not regulatory findings or clinical practice guidelines, and their ratings can be revised, so a rating of "minor" is a starting point for clinical judgment rather than a substitute for it.

A useful comparison is simvastatin, which is extensively metabolized by CYP3A4. Co-administration of simvastatin with strong CYP3A4 inhibitors has produced large, multi-fold increases in simvastatin exposure, which is why simvastatin carries FDA dose caps and boxed warnings for certain combinations [10]. Rosuvastatin, by bypassing CYP3A4 entirely, does not carry that specific vulnerability, which is the pharmacologic basis for calling it one of the lower-interaction-risk statins for patients also taking CYP3A4-dependent drugs like trazodone [2][10].

Monitoring: what to check, and when

For patients starting both medications, or adding one to an existing regimen, a short structured monitoring window addresses the residual pharmacodynamic risk without requiring a drug change.

First 2 to 4 weeks. Check orthostatic blood pressure (supine, then standing at 1 and 3 minutes) and ask directly about dizziness, lightheadedness, or near-syncope. This window captures the period when trazodone's alpha-blocking effect is most pronounced, particularly after a dose increase [7].

4 to 12 weeks. Check a lipid panel to confirm rosuvastatin is working, as would be done regardless of trazodone use. Ask about adherence to both drugs; some patients who develop dizziness quietly stop one or both medications without telling the prescriber.

Ongoing. Routine liver-function testing is not recommended for statin therapy in general under current cholesterol management guidance, which holds that hepatic monitoring is warranted only when symptoms suggest hepatotoxicity, reflecting the general assessment that statin benefit outweighs the low risk of serious liver injury. Creatine kinase should be checked only if the patient reports new muscle pain or weakness. There is no known mechanism by which trazodone would raise statin-related myopathy risk.

Who needs extra caution

Older adults (65 and older). Trazodone-related falls are a recognized geriatric concern, and some observational data have linked trazodone use to increased fall risk in nursing-home residents [8]. The precise magnitude reported in any single cohort study should be checked against the original publication before being cited as a fixed number, since study populations and adjustment methods vary; the directionally consistent finding across sources is that trazodone independently raises fall risk in this population, and adding any second drug with even mild orthostatic potential is reasonable to flag for extra vigilance.

Hepatic impairment. Rosuvastatin exposure rises roughly threefold in Child-Pugh class C cirrhosis, and doses above 10 mg are not recommended in active liver disease per the FDA label [3]. Trazodone clearance is also reduced in hepatic impairment. Both drugs may need dose reconsideration in a patient with significant liver disease, independent of each other.

Renal impairment. Rosuvastatin exposure increases with declining kidney function. The 40 mg dose is contraindicated at eGFR below 30 mL/min/1.73 m², and a 5 mg starting dose is recommended in severe renal impairment per the FDA label [3].

Concomitant CYP3A4 inhibitors. If a third drug in the regimen strongly inhibits CYP3A4 (for example fluconazole, diltiazem, or clarithromycin), trazodone levels may rise substantially per the trazodone label [7]. Rosuvastatin levels are not affected by CYP3A4 inhibitors, but the patient's overall sedation and hypotension burden goes up, which is the pharmacodynamic risk that actually matters in that scenario.

Contraindications independent of this pairing. Trazodone labeling carries its own warnings and contraindications, including use with monoamine oxidase inhibitors, that have nothing to do with rosuvastatin and should be reviewed on their own terms at the time of prescribing [7]. Rosuvastatin is contraindicated in active liver disease and in pregnancy; those restrictions also stand independent of trazodone use [3].

When switching statins might actually matter

If a patient needs a CYP3A4-metabolized statin, such as atorvastatin or simvastatin, alongside trazodone, the interaction calculus changes somewhat. Trazodone could theoretically compete for CYP3A4 capacity, though evidence of a clinically significant bidirectional effect at typical therapeutic doses is limited and not established by a dedicated trial.

The practical takeaway is narrower than "switch statins": if a patient is already stable on rosuvastatin and trazodone, there is no pharmacokinetic rationale to change the statin. For patients who need higher-potency LDL-C lowering, the STELLAR trial (N=2,431) found rosuvastatin produced greater LDL-C reductions than atorvastatin, simvastatin, and pravastatin across comparable doses, with rosuvastatin 40 mg reducing LDL-C by roughly 55 percent [11]. Choosing rosuvastatin in a patient on trazodone does not require sacrificing lipid-lowering potency.

Patient counseling points

Timing. Trazodone for insomnia is usually taken at bedtime. Rosuvastatin's roughly 19-hour half-life means its timing does not affect efficacy, so it can reasonably be taken in the morning [3]. Separating the two doses spaces out their peak plasma levels and may reduce cumulative daytime dizziness, though this is a practical suggestion rather than a labeled requirement.

Positional changes. Advise patients to rise slowly from sitting or lying positions, particularly in the first two weeks of trazodone therapy or after a dose increase. This simple habit reduces orthostatic episodes.

Muscle symptoms. Patients should report new muscle pain, tenderness, or weakness. Trazodone does not raise statin myopathy risk through any known pharmacokinetic mechanism, but patients on multiple drugs sometimes attribute a symptom to the wrong medication, so a directed history and a creatine kinase level when indicated can clarify the cause.

When to seek urgent care. Fainting, a fall resulting in injury, chest pain, or severe confusion after starting or adjusting either drug warrants same-day or emergency evaluation rather than waiting for a scheduled follow-up. Because trazodone is serotonergic, symptoms suggesting serotonin syndrome (agitation, high fever, muscle rigidity, rapid heart rate) should prompt urgent evaluation if the patient is also on another serotonergic drug; rosuvastatin itself has no serotonergic activity and does not contribute to that risk.

Evidence-status interaction assessment

Before dismissing this interaction as clinically irrelevant, verify:

• Current renal and hepatic function, since rosuvastatin dosing thresholds change with both [3]
• Any other CYP3A4-active drug in the regimen, since that changes trazodone exposure independent of rosuvastatin [7]
• Fall history, orthostatic symptoms, or use of other sedating or antihypertensive drugs
• Whether trazodone is being used at a low insomnia dose or a higher antidepressant dose, since the dizziness rate differs by dose [7]
• The current version of the interaction rating in whatever database is in use, since these ratings are periodically revised

Frequently asked questions

This article is a source-audited educational review. It does not replace individualized advice from the prescriber or pharmacist managing a specific patient's regimen, and the effect-size claims flagged above as unverified should be checked against the cited primary source before being restated as a fixed number.